Association between cerebral metabolism and Rey-Osterrieth Complex Figure Test performance in Alzheimer’s disease

Por Melrose, Rebecca J., Harwood, Dylan, Khoo, Theresa, Mandelkern, Mark, Sultzer, David L.
Publicado em 2013

CEREBROSPINAL FLUID BIOMARKERS IN CLINICAL SUBTYPES OF EARLY-ONSET ALZHEIMER’S DISEASE

Por Teng, Edmond, Yamasaki, Tritia R., Tran, Michelle, Hsiao, Julia J., Sultzer, David L., Mendez, Mario F.
Publicado em 2013

The neural correlates of naming and fluency deficits in Alzheimer’s disease: an FDG-PET study

Por Melrose, Rebecca J., Campa, Olivia M., Harwood, Dylan G., Osato, Sheryl, Mandelkern, Mark A., Sultzer, David L.
Publicado em 2009

Neuropsychological and Neuroimaging Markers in Early Versus Late-Onset Alzheimer’s Disease

Por Kaiser, Natalie C., Melrose, Rebecca J., Liu, Collin, Sultzer, David L., Jimenez, Elvira, Su, Michael, Monserratt, Lorena, Mendez, Mario F.
Publicado em 2012

Neurobiology of delusions, memory, and insight in Alzheimer’s disease

Por Sultzer, David L., Leskin, Lorraine P., Melrose, Rebecca J., Harwood, Dylan G., Narvaez, Theresa A., Ando, Timothy K., Mandelkern, Mark A.
Publicado no Am J Geriatr Psychiatry (2013)

Deep Brain Stimulation of the Basolateral Amygdala: Targeting Technique and Electrodiagnostic Findings

Por Langevin, Jean-Philippe, Chen, James W. Y., Koek, Ralph J., Sultzer, David L., Mandelkern, Mark A., Schwartz, Holly N., Krahl, Scott E.
Publicado no Brain Sci (2016)

Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes from the CATIE-AD Effectiveness Trial

Por Sultzer, David L., Davis, Sonia M., Tariot, Pierre N., Dagerman, Karen S., Lebowitz, Barry D., Lyketsos, Constantine G., Rosenheck, Robert A., Hsiao, John K., Lieberman, Jeffrey A., Schneider, Lon S.
Publicado em 2008

Metabolic Changes Associated with Second-generation Antipsychotic Use in Alzheimer’s Disease Patients: the CATIE-AD Study

Por Zheng, Ling, Mack, Wendy J., Dagerman, Karen S., Hsiao, John K., Lebowitz, Barry D., Lyketsos, Constantine G., Stroup, T. Scott, Sultzer, David L., Tariot, Pierre N., Vigen, Cheryl, Schneider, Lon S.
Publicado em 2009

Relapse Risk after Discontinuation of Risperidone in Alzheimer’s Disease

Por Devanand, D.P., Mintzer, Jacobo, Schultz, Susan K., Andrews, Howard F., Sultzer, David L., de la Pena, Danilo, Gupta, Sanjay, Colon, Sylvia, Schimming, Corbett, Pelton, Gregory H., Levin, Bruce
Publicado em 2012

Prediction of Relapse Following Discontinuation of Antipsychotic Treatment in Alzheimer’s disease: The Role of Hallucinations

Por Patel, Anjali N., Lee, Seonjoo, Andrews, Howard F., Pelton, Gregory H., Schultz, Susan K., Sultzer, David L., Mintzer, Jacobo, de la Pena, Danilo, Gupta, Sanjay, Colon, Sylvia, Schimming, Corbett, Levin, Bruce, Devanand, D.P.
Publicado no Am J Psychiatry (2016)

Neuropsychiatric symptoms in Alzheimer’s disease: Past progress and anticipation of the future

Por Geda, Yonas E., Schneider, Lon S., Gitlin, Laura N., Miller, David S., Smith, Gwenn S., Bell, Joanne, Evans, Jovier, Lee, Michael, Porsteinsson, Anton, Lanctôt, Krista L., Rosenberg, Paul B., Sultzer, David L., Francis, Paul T., Brodaty, Henry, Padala, P. P., Onyike, Chiadikaobi U., Ortiz, L. Agüera, Ancoli-Israel, Sonia, Bliwise, Donald L., Martin, Jennifer L., Vitiello, Michael V., Yaffe, Kristine, Zee, Phyllis C., Herrmann, Nathan, Lyketsos, Constantine G.
Publicado em 2013